Medigene AG Expands Its End-To-End Platform By Submitting Three Development Optimization Technology Patents To The European Patent Office
Source: menafn.com
📰 Switch Proteins News
Switch Proteins News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Switch Proteins. Real-time updates on events, politics, business and more.
Medigene's Global Research & Collaboration Agreement with BioNTech to Extend Beyond Initially Announced Term
Planegg/Martinsried, May 21, 2024. Medigene AG , an immuno-oncology platform company focusing on the discovery and development of differentiated T cell immunotherapies for solid tumors and BioNTech SE...
Planegg Martinsried Pamela Keck Prime Standard Chief Executive Officer End To Platform Switch Proteins
Source: marketscreener.com
Medigene's Global Research & Collaboration Agreement with BioNTech to Extend Beyond ...
Planegg/Martinsried, May 21, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of differentiated T cell immunotherapies for
Pamela Keck Planegg Martinsried Prime Standard Chief Executive Officer End To Platform Switch Proteins
Source: smdailyjournal.com
Medigene Presents at CAR-TCR Summit Europe Showcasing Unique Approach for Development of ...
Multiple members of management as expert speakers including Prof. Dr. Dolores Schendel, Chief Scientific Officer of Medigene, Dr. Barbara Lösch, Head of Technology & Innovation and Dr. Kirsty Crame, Vice
Source: smdailyjournal.com
Medigene presents new data for MDG2011, the first TCR in a novel KRAS library, demonstrating ...
Planegg/Martinsried, November 4, 2023. Medigene AG (Medigene, the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors,
United States San Diego Planegg Martinsried Pamela Keck Doloresj Schendel Society For Immunotherapy Of Cancer
Source: smdailyjournal.com